Drug Development Simulation
from lead optimization via proof of concept to marketing

General information
In this course the drug development process will be simulated, from the beginning to the end: from lead optimization through proof of concept phases and clinical studies, culminating in developing marketing strategies. This TI Pharma course provides its researchers with an interactive experience demonstrating the required competencies of the various players in the drug development process.

Objectives
Participants will work to achieve the following goals:
- Understanding the development process
- Understanding the role played by various relevant disciplines
- Experiencing relevant interactions and interfaces
- Learning the consequences of specific decisions and actions taken
- Learning what actions should be taken when carrying out a “real” process
- Teamwork/networking
- Developing one’s own set of learning objectives

Course duration
Five full day sessions, including evenings, over a single week (Monday morning through Friday afternoon 2 pm).

Participation
Participation is compulsory for TI Pharma post docs. A basic understanding of the industry’s drug development process is a prerequisite for this course.
TI Pharma will build the teams for each course, based on relevant industry background and certain participants’ areas of study.

Location
De Ruwenberg Conference Centre, Sint-Michielsgestel (www.ruwenberg.nl)

Course method
- Learning by experiencing; gaining practical experience!
- Participants have roles within development teams
- Participants take action and prepare decisions
- Faculty act as management, experts and authorities

Maximum number of attendees/language
Capacity for this course is 18 registered attendees. The course will take place in English.

Costs
TI Pharma fellows only pay their own expenses (travel, accommodation and food & drinks).
Rate 2009: € 990,- (travel excluded). These expenses will be charged to your employer.

Reference book
Drug Discovery and Development, H.P. Rang, Churchill Livingstone, Elsevier, London, 2006. This book will be provided by TI Pharma and will be sent to the participant after accepting the invitation.

Next run
March 30 – April 3, 2009
October 5 – 9, 2009

Course leader/contact
K.R. Huiberts, MSc karin.huiberts@tipharma.com 071 – 332 20 37

Would you like to join? Please contact Désirée Elderhorst, MSc by email at desiree.elderhorst@tipharma.com or via phone at 071 – 332 20 42.
Testimonials
a participant’s view

Andrea Hawe, post doc, LACDR:

“The DDES course was an interesting experience for me, as it offered the possibility to get insight in the drug development process by really performing the whole drug development process together with the team. During the simulation, the teams worked really well together and everyone became enthusiastic to be the ‘first on the market’. Furthermore, the course was a perfect opportunity to make contact to other TI Pharma employees.”

Harald Heemstra, post doc, Universiteit Utrecht, Dep. of Pharmaceutics:

“The simulation gives a unique opportunity to experience the drug development process from start to end. It is a very good course that lets you see where your research fits in the big picture.”

Maikel Wijtmans, post doc, LACDR:

“Starting the DDES course from TI Pharma, I had set myself the goal to get a better appreciation of the drug development process. The course itself was set up as a simulation: teams acted together in developing a drug while being faced with various deadlines and development-related problems, just as in real life. Naturally, this makes for an intense week, yet many hurdles were successfully taken by our team. In the end, I can say that I had achieved more than I had planned for: during the course, one is not a bystander or a listener but an actual developer and as such the dynamics of the development process are not just ‘appreciated’ but rather ‘fully experienced’.”